Do what is best for patient care.


Throughout our history, anytime something bad has happened to us, we have recovered—and have become our strongest. Masimo believes that when we come together, we can find a way forward.



Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, medical devices, and a wide array of sensors. We believe that Masimo SET® helps clinicians monitor in excess of approximately 100 million patients in healthcare settings around the world,1 and is the primary pulse oximetry technology at 17 of the top 20 hospitals listed in the 2017-2018 U.S. News & World Report Best Hospitals Honor Roll.

History of Masimo

Joe Kiani founded Masimo in 1989 as a private “garage start-up” company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry, the measurement of the oxygen saturation of arterial blood. His solution, Masimo SET® Measure-through Motion* and Low Perfusion™ pulse oximetry, was shown in a study comparing three pulse oximetry technologies to demonstrate the highest sensitivity and specificity in identifying desaturation events during conditions of motion and low perfusion.

Masimo Today

Today, Masimo is publicly traded and employs over 4,600 people worldwide, with annual revenues of approximately $800 million. Licensing agreements allow Masimo technology to work inside monitoring devices from a host of manufacturers, including Philips, Atom, Mindray North America, GE Medical, Spacelabs, and Zoll. Throughout its more than 25-year journey, Masimo’s mission – to improve patient outcomes and reduce the cost of care – has remained strong.

Featured Products

Radius™ PPG Tetherless Pulse Oximetry

Radius PPG provides industry-leading Masimo SET® pulse oximetry without a cabled connection to a monitor, allowing patients to move wirelessly and comfortably while still being continuously and reliably monitored. Wireless connection to a host device is simple to establish and each Radius PPG can easily pair with multiple devices (maintaining connection to any one device at a time), simplifying transfers between care areas. Automated by Masimo’s connectivity solutions, patient data can be used for remote clinician notification of changes in patient condition and automatically transferred to the hospital EMR.

Next Generation SedLine® Brain Function Monitoring

Root® with Next Generation SedLine Brain Function Monitoring helps clinicians monitor the state of the brain under anesthesia with bilateral data acquisition and processing of electroencephalogram (EEG) signals.

Next Generation SedLine Features:


Rad-67™ Pulse CO-Oximeter®

More Than a Conventional Pulse Oximeter

Noninvasive SpO2 and SpHb Spot-check Monitoring

Rad-67’s ability to provide portable spot-check monitoring measurements of both oxygen saturation and noninvasive hemoglobin makes it a single-device solution in multiple clinical and non-clinical settings, such as emergency rooms, pre-/post-surgery settings, and physicians’ offices. When used with the rainbow® DCI-mini sensor, Rad-67 provides spot-check monitoring with Next Generation SpHb. Next Generation SpHb technology significantly advances the forefront of noninvasive portable hemoglobin spot-check monitoring: SpHb field performance is enhanced across all hemoglobin ranges through faster measurement results and improved repeatability.

CCHD Screening with Pulse Oximetry

Congenital heart defects (CHDs) are the most common birth-related malformation. Critical CHDs (CCHDs) are life threatening and account for nearly 25% of all CHDs. Babies sent home with an undetected heart defect are at risk of serious complications within the first few days or weeks of life, requiring emergency care, and even at risk of dying. Traditionally, following birth, newborns were observed for evidence of CHDs by physical assessment and monitoring for common symptoms. Today, studies show that these methods alone can be unreliable and may fail to detect up to 36% of infants with CCHD before discharge. Adding screening with pulse oximetry can help diagnose CCHD before an infant becomes symptomatic.

Masimo Leadership Interviews



Recognition for Excellence

Masimo Rad-97™ Wins 2019 BIG Innovation Award
Masimo Founder and CEO Joe Kiani Honored with First IP Champion Award by the Intellectual Property Owners Education Foundation
Masimo Wins Participation in the FDA Innovation Challenge to Develop Devices that Prevent and Treat Opioid Use Disorder
Masimo Awarded Best Patient Monitoring Technology Manufacturer 2018 by Global Health & Pharma
Masimo CEO Joe Kiani Selected Person of the Year – SafeCare Magazine
Masimo Root Wins the GOLD 2015 Medical Design Excellence Award

Careers Opportunities at Masimo

Looking for uncommon opportunities with an extraordinary company?

That’s right, we’re looking for ‘what-ifers’, ‘never-say-never-ers’, and ‘world changers’—people who look beyond what others see—to join our expanding team. Granted, these are not ordinary job titles. But, then again we are not looking for ordinary people. We’re looking for people who can, do, and will make a difference.

Do you thrive on fascination and accomplishment? Strive to make each day better? Remain faithful to your promises? So do we. At Masimo, we develop innovative medical technologies and noninvasive patient monitoring solutions that solve ‘unsolvable’ problems. Our work makes a measureable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life.

So, if you’ve got a big vision, the desire to make a big impact, and a yearning for unlimited possibilities, then we have BIG plans for you! Discover what Masimo has to offer and you’ll find a thriving career and work environment designed to provide the freedom and support you need to achieve great things every day.
We think you’ll like what you see.